Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57,159,091
-
Total 13F shares
-
32,032,058
-
Share change
-
-119,113
-
Total reported value
-
$172,330,117
-
Put/Call ratio
-
717%
-
Price per share
-
$5.38
-
Number of holders
-
99
-
Value change
-
+$1,330,353
-
Number of buys
-
42
-
Number of sells
-
42
Institutional Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q3 2024
As of 30 Sep 2024,
Design Therapeutics, Inc. - Common Stock (DSGN) was held by
99 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,032,058 shares.
The largest 10 holders included
SR One Capital Management, LP, Logos Global Management LP, BlackRock, Inc., Frazier Life Sciences Management, L.P., BAKER BROS. ADVISORS LP, Point72 Asset Management, L.P., TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Almitas Capital LLC, and FMR LLC.
This page lists
98
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.